2.13  -0.21 (-8.97%)		11-21 16:00
Open: 2.34 High: 2.355 Volume: 3,907,972		Pre. Close: 2.34 Low: 2.11 Market Cap: 19(M)

Short term
Mid term
Targets	6-month :	2.86	1-year :	3.34
Resists	First :	2.45	Second :	2.86
Pivot price	1.95
Supports	First :	1.87	Second :	1.51
MAs	MA(5) :	2.15	MA(20) :	1.94
	MA(100) :	1.19	MA(250) :	1.14
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	78.3	D(3) :	77.7
RSI	RSI(14): 57.6
52-week	High :	3.29	Low :	0.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PALI ] has closed below upper band by 27.9%. Bollinger Bands are 34.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.36 - 2.37	2.37 - 2.38
Low:	2.08 - 2.1	2.1 - 2.1
Close:	2.11 - 2.13	2.13 - 2.15

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Fri, 21 Nov 2025
Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week - Yahoo Finance

Mon, 17 Nov 2025
Palisade Bio (PALI) Price Target Increased by 45.83% to 11.90 - Nasdaq

Mon, 10 Nov 2025
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - Zacks Investment Research

Thu, 06 Nov 2025
All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy - Yahoo Finance

Wed, 29 Oct 2025
Palisade Bio’s Unexpected Surge: Analyzing Recent Developments - StocksToTrade

Tue, 07 Oct 2025
Is It Too Late to Buy Palisade Bio? - StocksToTrade

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	149 (M)
Shares Float	6 (M)
Held by Insiders	0 (%)
Held by Institutions	40.9 (%)
Shares Short	7,590 (K)
Shares Short P.Month	1,040 (K)

EPS	-2.07
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-87.9 %
Return on Equity (ttm)	-228.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.08
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-1.03
PEG Ratio	0
Price to Book value	6.08
Price to Sales	0
Price to Cash Flow	-31.49

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.